BR112017006940A2 - triazolopirazinonas como inibidores de pde1 - Google Patents
triazolopirazinonas como inibidores de pde1Info
- Publication number
- BR112017006940A2 BR112017006940A2 BR112017006940A BR112017006940A BR112017006940A2 BR 112017006940 A2 BR112017006940 A2 BR 112017006940A2 BR 112017006940 A BR112017006940 A BR 112017006940A BR 112017006940 A BR112017006940 A BR 112017006940A BR 112017006940 A2 BR112017006940 A2 BR 112017006940A2
- Authority
- BR
- Brazil
- Prior art keywords
- triazolopyrazinones
- pde1 inhibitors
- pde1
- inhibitors
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção proporciona triazolopirazinonas como inibidores de pde1 e seu uso como um medicamento, em particular para o tratamento de distúrbios neurodegenerativos e distúrbios psiquiátricos
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400582 | 2014-10-10 | ||
PCT/EP2015/073417 WO2016055618A1 (en) | 2014-10-10 | 2015-10-09 | Triazolopyrazinones as pde1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017006940A2 true BR112017006940A2 (pt) | 2018-01-09 |
Family
ID=58698606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017006940A BR112017006940A2 (pt) | 2014-10-10 | 2015-10-09 | triazolopirazinonas como inibidores de pde1 |
Country Status (25)
Country | Link |
---|---|
US (1) | US10150771B2 (pt) |
EP (1) | EP3204387B1 (pt) |
JP (1) | JP6596489B2 (pt) |
KR (1) | KR20170066417A (pt) |
CN (1) | CN106715438B (pt) |
AR (1) | AR102227A1 (pt) |
AU (1) | AU2015329898A1 (pt) |
BR (1) | BR112017006940A2 (pt) |
CA (1) | CA2961986A1 (pt) |
CL (1) | CL2017000817A1 (pt) |
CO (1) | CO2017002708A2 (pt) |
DO (1) | DOP2017000080A (pt) |
EA (1) | EA201790575A1 (pt) |
EC (1) | ECSP17018120A (pt) |
ES (1) | ES2735733T3 (pt) |
IL (1) | IL251420A0 (pt) |
MX (1) | MX2017004510A (pt) |
PE (1) | PE20180024A1 (pt) |
PH (1) | PH12017500621A1 (pt) |
RU (1) | RU2017111888A (pt) |
SG (1) | SG11201702874YA (pt) |
SV (1) | SV2017005419A (pt) |
TN (1) | TN2017000099A1 (pt) |
TW (1) | TW201629064A (pt) |
WO (1) | WO2016055618A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
TW201643167A (zh) * | 2015-04-22 | 2016-12-16 | H 朗德貝克公司 | 作爲pde1抑制劑之咪唑並三酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) * | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
JOP20170164A1 (ar) * | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
ES2967489T3 (es) * | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
MX2019007803A (es) | 2016-12-28 | 2019-08-29 | Dart Neuroscience Llc | Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2). |
AR112457A1 (es) * | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
KR20200099154A (ko) | 2017-12-14 | 2020-08-21 | 하. 룬드벡 아크티에셀스카브 | 1H-피라졸로[4,3-b]피리딘의 투여를 포함하는 조합 치료제 |
TW201927784A (zh) * | 2017-12-20 | 2019-07-16 | 丹麥商H 朗德貝克公司 | 作為pde1抑制劑之大環 |
JP7194738B2 (ja) | 2017-12-20 | 2022-12-22 | ハー・ルンドベック・アクチエゼルスカベット | PDE1阻害剤としてのピラゾロ[3,4-b]ピリジン及びイミダゾ[1,5-b]ピリダジン |
US10766893B2 (en) * | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
US11453673B2 (en) * | 2018-02-06 | 2022-09-27 | Eli Lilly And Company | Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
EP1626971B1 (de) | 2003-05-09 | 2011-08-10 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
WO2008070095A1 (en) | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
SI2152712T1 (sl) | 2007-05-11 | 2012-03-30 | Pfizer | Amino heterociklične spojine |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
WO2010026214A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
EA201170772A1 (ru) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
WO2011153136A1 (en) * | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP3181566A1 (en) | 2010-09-20 | 2017-06-21 | Ironwood Pharmaceuticals, Inc. | Imidazotriazinone compounds |
WO2012040048A2 (en) | 2010-09-21 | 2012-03-29 | Schering Corporation | Triazolopyrazinones as p2x7 receptor antagonists |
US10561656B2 (en) * | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN106905324B (zh) | 2011-10-10 | 2018-09-25 | H.隆德贝克有限公司 | 具有咪唑并吡嗪酮骨架的pde9抑制剂 |
CN104093720B (zh) | 2012-01-26 | 2017-04-12 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
BR112014031730B1 (pt) | 2012-06-18 | 2023-05-16 | Dart Neuroscience (Cayman) Ltd | Compostos ou sais farmaceuticamente aceitáveis dos mesmos e seu uso |
RU2679142C2 (ru) | 2013-03-15 | 2019-02-06 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
JP2017527606A (ja) | 2014-09-18 | 2017-09-21 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | 三環系誘導体 |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
TW201639851A (zh) | 2015-03-16 | 2016-11-16 | 大日本住友製藥股份有限公司 | 雙環咪唑衍生物 |
TW201643167A (zh) | 2015-04-22 | 2016-12-16 | H 朗德貝克公司 | 作爲pde1抑制劑之咪唑並三酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
ES2967489T3 (es) | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
MA46621A (fr) | 2016-10-28 | 2021-06-02 | H Lundbeck As | Traitements combinés comprenant l'administration d'imidazopyrazinones |
MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
-
2015
- 2015-10-08 TW TW104133183A patent/TW201629064A/zh unknown
- 2015-10-09 JP JP2017518482A patent/JP6596489B2/ja active Active
- 2015-10-09 SG SG11201702874YA patent/SG11201702874YA/en unknown
- 2015-10-09 EP EP15787486.8A patent/EP3204387B1/en active Active
- 2015-10-09 EA EA201790575A patent/EA201790575A1/ru unknown
- 2015-10-09 KR KR1020177009566A patent/KR20170066417A/ko unknown
- 2015-10-09 RU RU2017111888A patent/RU2017111888A/ru unknown
- 2015-10-09 BR BR112017006940A patent/BR112017006940A2/pt not_active Application Discontinuation
- 2015-10-09 AU AU2015329898A patent/AU2015329898A1/en not_active Abandoned
- 2015-10-09 MX MX2017004510A patent/MX2017004510A/es unknown
- 2015-10-09 CA CA2961986A patent/CA2961986A1/en not_active Abandoned
- 2015-10-09 US US15/517,348 patent/US10150771B2/en active Active
- 2015-10-09 PE PE2017000481A patent/PE20180024A1/es not_active Application Discontinuation
- 2015-10-09 WO PCT/EP2015/073417 patent/WO2016055618A1/en active Application Filing
- 2015-10-09 CN CN201580052980.2A patent/CN106715438B/zh active Active
- 2015-10-09 ES ES15787486T patent/ES2735733T3/es active Active
- 2015-10-09 AR ARP150103269A patent/AR102227A1/es unknown
- 2015-10-09 TN TN2017000099A patent/TN2017000099A1/en unknown
-
2017
- 2017-03-21 DO DO2017000080A patent/DOP2017000080A/es unknown
- 2017-03-22 CO CONC2017/0002708A patent/CO2017002708A2/es unknown
- 2017-03-24 EC ECIEPI201718120A patent/ECSP17018120A/es unknown
- 2017-03-27 IL IL251420A patent/IL251420A0/en unknown
- 2017-03-31 SV SV2017005419A patent/SV2017005419A/es unknown
- 2017-04-04 CL CL2017000817A patent/CL2017000817A1/es unknown
- 2017-04-04 PH PH12017500621A patent/PH12017500621A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
TN2017000099A1 (en) | 2018-07-04 |
KR20170066417A (ko) | 2017-06-14 |
US10150771B2 (en) | 2018-12-11 |
WO2016055618A1 (en) | 2016-04-14 |
PE20180024A1 (es) | 2018-01-09 |
EP3204387A1 (en) | 2017-08-16 |
CN106715438B (zh) | 2019-04-12 |
SG11201702874YA (en) | 2017-05-30 |
ECSP17018120A (es) | 2017-08-31 |
MX2017004510A (es) | 2017-06-28 |
SV2017005419A (es) | 2017-06-07 |
AR102227A1 (es) | 2017-02-15 |
US20170298072A1 (en) | 2017-10-19 |
CN106715438A (zh) | 2017-05-24 |
JP6596489B2 (ja) | 2019-10-23 |
EA201790575A1 (ru) | 2017-07-31 |
ES2735733T3 (es) | 2019-12-20 |
CL2017000817A1 (es) | 2017-11-03 |
CO2017002708A2 (es) | 2017-06-30 |
CA2961986A1 (en) | 2016-04-14 |
IL251420A0 (en) | 2017-05-29 |
RU2017111888A (ru) | 2018-11-12 |
EP3204387B1 (en) | 2019-06-12 |
DOP2017000080A (es) | 2017-05-15 |
TW201629064A (zh) | 2016-08-16 |
JP2017530173A (ja) | 2017-10-12 |
AU2015329898A1 (en) | 2017-03-30 |
PH12017500621A1 (en) | 2017-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017006940A2 (pt) | triazolopirazinonas como inibidores de pde1 | |
DOP2017000254A (es) | Imidazopirazinonas como inhibidores de pde1 | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
ECSP16061208A (es) | Quinazolin-thf-aminas como inhibidores de pde1 | |
CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
ECSP16071574A (es) | Hexahidrofuropirroles como inhibidores de pde1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |